Phase II clinical trial - Sein métastatique triple négatif

TOPOLOGY
Sein métastatique triple négatif
Essai clinique fermé
Public cible
Adulte
A phase II study to evaluate the efficacy and toxicities;of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.
Description de l'essai
Efficacy of PLX038 on response rate.;Primary endpoint:;Best tumor response (defined as PR or CR in the first 6 months of treatment, assessed by investigators per RECIST v1.1 criteria).
Liens utiles
Lien de l'essai
Vignette
FRANCOIS-CLEMENT BIDARD
Investigateur principal
Vignette
FRANCOIS-CLEMENT BIDARD
Investigateur principal